These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 30923820)

  • 1. Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma.
    Jansen YJL; Rozeman EA; Mason R; Goldinger SM; Geukes Foppen MH; Hoejberg L; Schmidt H; van Thienen JV; Haanen JBAG; Tiainen L; Svane IM; Mäkelä S; Seremet T; Arance A; Dummer R; Bastholt L; Nyakas M; Straume O; Menzies AM; Long GV; Atkinson V; Blank CU; Neyns B
    Ann Oncol; 2019 Jul; 30(7):1154-1161. PubMed ID: 30923820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discontinuation of anti-PD-1 monotherapy in advanced melanoma-Outcomes of daily clinical practice.
    van Zeijl MCT; van den Eertwegh AJM; Wouters MWJM; de Wreede LC; Aarts MJB; van den Berkmortel FWPJ; de Groot JB; Hospers GAP; Kapiteijn E; Piersma D; van Rijn RS; Suijkerbuijk KPM; Ten Tije AJ; van der Veldt AAM; Vreugdenhil G; van der Hoeven JJM; Haanen JBAG
    Int J Cancer; 2022 Jan; 150(2):317-326. PubMed ID: 34520567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.
    Ribas A; Hamid O; Daud A; Hodi FS; Wolchok JD; Kefford R; Joshua AM; Patnaik A; Hwu WJ; Weber JS; Gangadhar TC; Hersey P; Dronca R; Joseph RW; Zarour H; Chmielowski B; Lawrence DP; Algazi A; Rizvi NA; Hoffner B; Mateus C; Gergich K; Lindia JA; Giannotti M; Li XN; Ebbinghaus S; Kang SP; Robert C
    JAMA; 2016 Apr; 315(15):1600-9. PubMed ID: 27092830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy of anti-PD-1 agents in acral and mucosal melanoma.
    Shoushtari AN; Munhoz RR; Kuk D; Ott PA; Johnson DB; Tsai KK; Rapisuwon S; Eroglu Z; Sullivan RJ; Luke JJ; Gangadhar TC; Salama AK; Clark V; Burias C; Puzanov I; Atkins MB; Algazi AP; Ribas A; Wolchok JD; Postow MA
    Cancer; 2016 Nov; 122(21):3354-3362. PubMed ID: 27533633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma.
    Zimmer L; Apuri S; Eroglu Z; Kottschade LA; Forschner A; Gutzmer R; Schlaak M; Heinzerling L; Krackhardt AM; Loquai C; Markovic SN; Joseph RW; Markey K; Utikal JS; Weishaupt C; Goldinger SM; Sondak VK; Zager JS; Schadendorf D; Khushalani NI
    Eur J Cancer; 2017 Apr; 75():47-55. PubMed ID: 28214657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world experience with elective discontinuation of PD-1 inhibitors at 1 year in patients with metastatic melanoma.
    Pokorny R; McPherson JP; Haaland B; Grossmann KF; Luckett C; Voorhies BN; Sageser DS; Wallentine J; Tolman Z; Hu-Lieskovan S; Swami U
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33500258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab.
    Muto Y; Kitano S; Tsutsumida A; Namikawa K; Takahashi A; Nakamura Y; Yamanaka T; Yamamoto N; Yamazaki N
    J Dermatol; 2019 Jun; 46(6):498-506. PubMed ID: 30945333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial.
    Mulder EEAP; de Joode K; Litière S; Ten Tije AJ; Suijkerbuijk KPM; Boers-Sonderen MJ; Hospers GAP; de Groot JWB; van den Eertwegh AJM; Aarts MJB; Piersma D; van Rijn RS; Kapiteijn E; Vreugdenhil G; van den Berkmortel FWPJ; Hoop EO; Franken MG; Ryll B; Rutkowski P; Sleijfer S; Haanen JBAG; van der Veldt AAM
    BMC Cancer; 2021 Mar; 21(1):323. PubMed ID: 33765967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
    Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T
    JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II multicentre study of plasminogen activator inhibitor-1 inhibitor (TM5614) plus nivolumab for treating anti-programmed cell death 1 antibody-refractory malignant melanoma: TM5614-MM trial.
    Fujimura T; Yoshino K; Kato H; Fukushima S; Ishizuki S; Otsuka A; Matsushita S; Amagai R; Muto Y; Yamazaki E; Kambayashi Y; Yahata T; Miyata T; Fujisawa Y; Asano Y
    Br J Dermatol; 2024 Oct; 191(5):691-697. PubMed ID: 38833158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial.
    Naing A; Wong DJ; Infante JR; Korn WM; Aljumaily R; Papadopoulos KP; Autio KA; Pant S; Bauer TM; Drakaki A; Daver NG; Hung A; Ratti N; McCauley S; Van Vlasselaer P; Verma R; Ferry D; Oft M; Diab A; Garon EB; Tannir NM
    Lancet Oncol; 2019 Nov; 20(11):1544-1555. PubMed ID: 31563517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.
    Pires da Silva I; Ahmed T; Reijers ILM; Weppler AM; Betof Warner A; Patrinely JR; Serra-Bellver P; Allayous C; Mangana J; Nguyen K; Zimmer L; Trojaniello C; Stout D; Lyle M; Klein O; Gerard CL; Michielin O; Haydon A; Ascierto PA; Carlino MS; Lebbe C; Lorigan P; Johnson DB; Sandhu S; Lo SN; Blank CU; Menzies AM; Long GV
    Lancet Oncol; 2021 Jun; 22(6):836-847. PubMed ID: 33989557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes after progression of disease with anti-PD-1/PD-L1 therapy for patients with advanced melanoma.
    Patrinely JR; Baker LX; Davis EJ; Song H; Ye F; Johnson DB
    Cancer; 2020 Aug; 126(15):3448-3455. PubMed ID: 32463489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose ipilimumab combined with anti-PD-1 immunotherapy in patients with metastatic melanoma following anti-PD-1 treatment failure.
    Klee G; Kurzhals J; Hagelstein V; Zillikens D; Recke A; Langan EA; Terheyden P
    Melanoma Res; 2021 Oct; 31(5):464-471. PubMed ID: 34284462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of ipilimumab after anti-PD-1 therapy in sequential treatment of metastatic melanoma patients - Real world evidence.
    Cybulska-Stopa B; Rogala P; Czarnecka AM; Ługowska I; Teterycz P; Galus Ł; Rajczykowski M; Dawidowska A; Piejko K; Suwiński R; Mackiewicz J; Rutkowski P
    Adv Med Sci; 2020 Sep; 65(2):316-323. PubMed ID: 32554313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitiligo expansion and extent correlate with durable response in anti-programmed death 1 antibody treatment for advanced melanoma: A multi-institutional retrospective study.
    Matsuya T; Nakamura Y; Matsushita S; Tanaka R; Teramoto Y; Asami Y; Uehara J; Aoki M; Yamamura K; Nakamura Y; Fujisawa Y; Livingstone E; Zimmer L; Schadendorf D; Kagamu H; Fujimoto M; Honma M; Ishida-Yamamoto A; Araki R; Yamamoto A
    J Dermatol; 2020 Jun; 47(6):629-635. PubMed ID: 32275100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies.
    Algazi AP; Tsai KK; Shoushtari AN; Munhoz RR; Eroglu Z; Piulats JM; Ott PA; Johnson DB; Hwang J; Daud AI; Sosman JA; Carvajal RD; Chmielowski B; Postow MA; Weber JS; Sullivan RJ
    Cancer; 2016 Nov; 122(21):3344-3353. PubMed ID: 27533448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis.
    Beaver JA; Hazarika M; Mulkey F; Mushti S; Chen H; He K; Sridhara R; Goldberg KB; Chuk MK; Chi DC; Chang J; Barone A; Balasubramaniam S; Blumenthal GM; Keegan P; Pazdur R; Theoret MR
    Lancet Oncol; 2018 Feb; 19(2):229-239. PubMed ID: 29361469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis.
    Alrabadi NN; Abushukair HM; Ababneh OE; Syaj SS; Al-Horani SS; Qarqash AA; Darabseh OA; Al-Sous MM; Al-Aomar SR; Ahmed YB; Haddad R; Al Qarqaz FA
    Clin Transl Oncol; 2021 Sep; 23(9):1885-1904. PubMed ID: 33877531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Open-label, phase II study of talimogene laherparepvec plus pembrolizumab for the treatment of advanced melanoma that progressed on prior anti-PD-1 therapy: MASTERKEY-115.
    Robert C; Gastman B; Gogas H; Rutkowski P; Long GV; Chaney MF; Joshi H; Lin YL; Snyder W; Chesney JA
    Eur J Cancer; 2024 Aug; 207():114120. PubMed ID: 38870745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.